Welcome to our dedicated page for Rigel Pharmaceuticals SEC filings (Ticker: RIGL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Rigel Pharmaceuticals' SEC filings document the regulatory record of a Delaware biotechnology company with common stock listed on Nasdaq under RIGL. Its 8-K reports frequently furnish operating results, product revenue trends, collaboration revenue and business updates tied to TAVALISSE, GAVRETO, REZLIDHIA and development programs such as R289.
The filings also cover material agreements, license and collaboration disclosures, capital-structure information for common stock, and governance matters. Proxy materials describe shareholder voting items, board matters, executive compensation and equity awards, while material-event filings record changes affecting agreements, financial reporting and corporate governance.
Rigel Pharmaceuticals EVP & Chief Financial Officer Dean L. Schorno exercised stock options and settled related taxes in shares. On June 1, 2026, he exercised options for 2,181 shares of common stock at $12.70 per share and 1,200 shares at $18.70 per share. To cover tax obligations, 928 shares of common stock were disposed of at a value of $29.86 per share, a tax-withholding transaction rather than an open-market sale. Following these transactions, he directly held 78,790 shares of Rigel common stock. The filing also notes all share amounts reflect a one-for-ten reverse stock split effective June 27, 2024.
RIGEL PHARMACEUTICALS INC executive David A. Santos, EVP and Chief Commercial Officer, reported a small share disposition related to taxes. On this date, 874 shares of common stock were delivered at $29.86 per share to cover tax obligations. After this tax-withholding event, Santos directly holds 61,996 shares of common stock, indicating that his overall ownership position remains largely unchanged.
RIGEL PHARMACEUTICALS INC EVP and Chief Medical Officer Lisa Rojkjaer reported a tax-related share disposition. On June 1, 2026, 850 shares of Common Stock were transferred at $29.86 per share to cover an exercise price or tax liability by delivering securities.
After this transaction, she directly owned 34,003 shares of Rigel common stock. The filing reflects a tax-withholding disposition rather than an open-market purchase or sale.
RIGEL PHARMACEUTICALS INC CEO and President Raul R. Rodriguez reported a Form 4 transaction involving a tax-related share disposition. On June 1, 2026, 2,424 shares of Common Stock were delivered at $29.86 per share to satisfy tax obligations. After this transaction, Rodriguez directly holds 279,593 shares of Common Stock, indicating the event reflects routine tax withholding rather than an open-market trade.
RIGEL PHARMACEUTICALS INC executive Raymond J. Furey reported a small tax-related share disposition. On June 1, 2026, 877 shares of common stock were delivered at $29.86 per share to cover tax obligations, a non‑market transaction classified as a tax-withholding disposition. Following this, he directly holds 50,936 common shares, indicating the adjustment is minor relative to his remaining position.
RIGEL PHARMACEUTICALS INC director Ali-Jackson Kamil reported an open-market sale of 2,500 shares of Common Stock on May 26, 2026, at an average price of $29.17 per share. Following the sale, the director directly holds 12,625 shares. The transaction was effected under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025.
Rigel Pharmaceuticals reported results from its 2026 annual stockholder meeting. Stockholders approved amendments to the 2018 Equity Incentive Plan and the 2000 Employee Stock Purchase Plan, adding 500,000 and 360,000 shares of common stock, respectively, for future equity grants and purchases.
All three director nominees were elected to serve until the 2029 annual meeting. Stockholders also approved, on an advisory basis, executive compensation as described in the proxy statement and ratified Ernst & Young LLP as Rigel’s independent registered public accounting firm for the fiscal year ending December 31, 2026.
Wasman Jane reported acquisition or exercise transactions in this Form 4 filing.
RIGEL PHARMACEUTICALS INC director Jane Wasman received an equity grant of 5,750 shares of Common Stock. The award is structured as Restricted Stock Units that will fully vest on the date prior to the company’s next Annual Meeting, as long as she continues serving on the Board of Directors.
Following this grant, her direct holdings increase to 18,250 shares, reflecting routine, compensation-related equity rather than an open-market stock purchase.
RIGEL PHARMACEUTICALS INC director Walter H. Moos received an equity award. On 2026-05-15, he was granted 5,750 shares of Common Stock at a grant price of $0.00 per share through a Restricted Stock Unit (RSU) award.
The footnote states these shares will be acquired only when the RSUs fully vest on the date prior to the company’s next Annual Meeting, as long as he continues serving on the Board of Directors. After this award, his direct holdings are 18,472 Common Stock shares.